Tagged with scienceindustries

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Switzerland Switzerland is a highly decentralised nation where much of the decision-making power lies within individual Cantons and where the Federal presidency is rotated annually. To consistently keep industry interests on the national agenda against this backdrop, a dense network of well-resourced and highly sophisticated professional associations has evolved in Switzerland.…

Switzerland Dr Stephan Mumenthaler, director of scienceindustries, highlights Switzerland’s strong position in the healthcare, life sciences, and pharmaceutical sectors and explores the nation’s commitment to innovation, sustainability, and maintaining global competitiveness.   Switzerland remains a premier destination for the healthcare, life sciences, and pharmaceutical industries, consistently ranking among the top countries…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…

Switzerland Dr. Beat Moser, Director General of scienceindustries, the association representing the Swiss science-driven industries, and Jürg Granwehr, head of its pharma department, explain the open concept of scienceindustries, with science-based innovation at its heart; and why Switzerland is competitive in international life sciences markets. What are some of the unique…